CD274 and neoplasm: For example, immune-checkpoint inhibitors (ICIs) that target programmed death ligand-1 (PD-L1) or cytotoxic T lymphocyte-4 (CTLA-4) restore the cytotoxic activity of lymphocytes against the tumor, and preclinical studies recently demonstrated that ICIs synergize with the therapeutic effect of PDT.